<unk>  is approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of severe asthma in patients aged six years or older and with an eosinophilic phenotype in combination with other medicines used to treat asthma. In the European Union it is approved as an add-on treatment for severe refractory eosinophilic asthma in adults. In studies,<unk>  cut the necessity for hospitalisation due to asthma exacerbations in half, as compared to placebo. In December 2017, the FDA expanded<unk> 's indication to treat adults with eosinophilic granulomatosis with polyangiitis, which is a rare autoimmune condition that can cause vasculitis. In September 2020, the FDA expanded<unk> 's indication to treat adults and children aged twelve years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.
Mepolizumab
Vedolizumab
Certolizumab pegol
Nemolizumab
Natalizumab
Belatacept
Brolucizumab
Reslizumab